Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of the Virologic Effect of Two Different Nucleoside Treatment Strategies (Zidovudine Versus Zidovudine in Combination With Didanosine) for HIV Infection in Subjects With CD4+ Counts >= 550 Cells/mm3

NCT00001057 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT00001057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00001057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of the Virologic Effect of Two Different Nucleoside Treatment Strategies (Zidovudine Versus Zidovudine in Combination With Didanosine) for HIV Infection in Subjects With CD4+ Counts >= 550 Cells/mm3
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
May 31, 1995
Enrollment
105
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections